An interactive webinar on Indian pharmaceutical products was organized

On December 18, 2020, the Embassy of India in Baku organized an online interactive webinar on Indian pharmaceuticals with the participation of four major pharmaceutical companies, Lupine Limited, Cadila Healthcare Limited, Glenmark Limited and OPES Healthcare Limited. The webinar was attended by business representatives from India and Azerbaijan, as well as importers from the Azerbaijani pharmaceutical industry.

Speaking at the webinar, Indian Ambassador to Azerbaijan B. Vanlalvavna stressed the position of Indian pharmaceutical companies in the world, noting that India exported $ 11.5 million worth of pharmaceuticals to Azerbaijan in 2019, which is the highest in India, the embassy told Trend. accounts for 3.9% of total pharmaceutical exports. The ambassador said that this is lower than the potential between the two countries in the sector. The Azerbaijani market plays an important role as it has the potential to become a center for pharmaceutical products for neighboring CIS countries. Thus, there are great opportunities for Indian pharmaceutical companies to expand their coverage in Azerbaijan.

Dr. Cadila Healthcare Limited, President of Cadila Healthcare Limited, which has a strong trade coverage in the United States, France, Spain, Brazil and Mexico and is expanding its operations in Latin America, Africa and the Middle East, as well as Asia Pacific. Amrut Naik informed the participants about the company and its products. He said the CyCov-D COVID-19 vaccine, developed by Zydus Cadilla, is in the final stages of clinical trial and will be ready for sale in the first quarter of 2021.

Mr. Deepak Sharma, CIS Business Director of Glenmark Ukraine LLC, which has a portfolio of more than 165 unbranded products, represented Glenmark at the webinar and spoke about Glenmark's activities, production and sales opportunities, features, as well as the company's provided extensive information on innovative research and development activities.

Mr. Ram Iyer, General Manager of Lupine Limited, provided information on Lupine Limited and its portfolio of specific anti-tuberculosis drugs and ARV products, and talked about future plans in this therapeutic field. Mr. Hitesh Soni, Director of OPES Health Care Limited, spoke about the company, which has strong coverage in Latin America, Europe, the United States, China and the CIS. 9 OPES drugs and 7 supplements have been registered in Azerbaijan, and the registration of 21 drugs continues. From Azerbaijan Mr. Anar Latifov -director of Makromed company and Ulviya Azmammadova, gave brief information on the pharmaceutical market, coverage, state regulations and law of Azerbaijan and explained the system of medicine  prices in Azerbaijan.

India is a well-known and fast-growing force in the global pharmaceutical industry. With a 20% share of global supplies and 62% of global vaccine demand, India is the world's largest supplier of non-branded drugs. India is the only country outside the United States to have the largest number of pharmaceutical plants (more than 262, including Active Pharmaceuticals) that meet US Food and Drug Administration standards. There are more than 3,000 pharmaceutical companies in the country with a strong network of more than 10,500 manufacturing facilities. During the COVID-19 pandemic, India played the role of "Pharmacy of the World" by supplying drugs to more than 150 countries. India's pharmaceutical industry is currently worth $ 41 billion.